A Comprehensive Guide to the Latest Landscape of Type 1 Diabetes: In-Depth Analysis of Immune Imbalance Core Mechanisms, RAGE and Teplizumab Targets, and Stem Cell Therapy

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic β cells, leading to absolute insulin deficiency, persistent hyperglycemia, and metabolic disorders. Clinical symptoms include polyuria, polydipsia, polyphagia, weight loss, fatigue, and blurred vision. If left untreated, it can progress to diabetic ketoacidosis (DKA), presenting with nausea, vomiting, abdominal pain, and altered consciousness. The incidence is higher in children and adolescents, accounting for 43.3% of new cases, while adult-onset accounts for 62%. Risk factors include genetic predisposition (such as HLA-DR3/DR4 genotypes increasing risk) and environmental triggers (such as viral infections, early exposure to cow's milk proteins or gluten).

The global prevalence of the disease continues to rise. According to the International Diabetes Federation (IDF) 2025 data, there are approximately 9.5 million people living with T1D worldwide, including about 1.85 million children and adolescents under 20 years old. Incidence varies by region, with the highest rates in high-income countries like Finland and Australia, while low-income countries may have underreported figures due to limited monitoring; projections estimate 14.7 million patients globally by 2040. Family history increases risk, but 90% of patients have no family history. In low-income countries, life expectancy is significantly reduced—for a 10-year-old diagnosed child, expected remaining lifespan drops from 66 years in high-income countries to as low as 6 years.

Figure 2. Number of people with type 1 diabetes by world region (A) and by country income level (B) in 2025

Pathogenesis

The pathogenesis of T1D involves interactions among genetic susceptibility, environmental triggers, and autoimmune responses. Genetic factors account for 40-50% of risk, primarily linked to the HLA region, such as high-risk haplotypes DR3-DQ2 and DR4-DQ8, which impair immune tolerance. Environmental factors (such as enterovirus infections, gut microbiome dysbiosis, vitamin D deficiency) trigger autoimmunity, leading to T cell-mediated β cell destruction. The disease progresses in stages: Stage 1 (autoantibody-positive with normal blood glucose), Stage 2 (autoantibody-positive with dysglycemia), Stage 3 (clinical symptoms + insulin dependence). β cell heterogeneity (differential susceptibility to stress and antigen presentation) exacerbates damage, and adults often have concurrent insulin resistance, including increased hepatic glucose production, reduced muscle glucose uptake, and elevated free fatty acids.

Figure 3. The process of genetic-environmental-immune interactions leading to β cell destruction

Diagnosis and Treatment

Diagnosis relies on blood glucose and HbA1c testing, combined with autoantibody confirmation (such as GAD, IA-2, IAA, ICA) to verify autoimmune etiology. The 2026 ADA guidelines expand screening: individuals with a family history or high risk are recommended for autoantibody screening, with positive cases monitored for glycemic progression using continuous glucose monitoring (CGM) assistance. Public screening can reduce DKA incidence by up to 50%.

Figure 4. Diagnostic workflow for suspected new-onset type 1 diabetes in adults based on White European population data

Lifelong insulin replacement is the cornerstone, including basal-bolus regimens, multiple daily injections (MDI), or pump therapy. Automated insulin delivery (AID) systems integrating CGM and pumps improve glycemic control and are recommended as first-line, especially for children, pregnant women, and those with severe insulin deficiency. Adjunctive therapies like glucagon-like peptide-1 (GLP-1) agonists help protect against hypoglycemia-related vascular damage.

Cutting-Edge Research Advances

Type 1 diabetes (T1D) research focuses on prevention, immunomodulation, β cell replacement, and smart therapies. Teplizumab, the first FDA-approved immunotherapy, delays clinical onset by 24-32 months in stage 2 patients and preserves β cell function. In 2026, expanded approval is anticipated for newly diagnosed stage 3 patients, along with efficacy data in children aged 0-7 years. Yale University-led clinical studies show the drug modulates T cells to reduce autoimmune attack, significantly extending the symptom-free period.

Figure 5. Mechanism of action of teplizumab

Stem cell therapy has made significant strides: A 2025 Stanford University study used hematopoietic stem cells combined with islet transplantation in mouse models to fully cure T1D by resetting the immune system and protecting transplanted cells from rejection. The approach achieved 100% cure in 9 long-term T1D mice, paving the way for human clinical trials. The University of California, San Francisco (UCSF) initiated minimally invasive islet transplantation in 2025, with early results showing improved glucose control.

Figure 6. Schematic of stem cell (SCs) differentiation into insulin-secreting β cells in pancreatic islets

Automated insulin delivery (AID) systems have advanced with multi-hormone delivery (insulin + glucagon/pramlintide) and meal announcement-free algorithms. The University of Virginia's AIDANET neural network fully closed-loop system controls blood glucose effectively without user input in testing. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2025 conference reported these upgrades increase time in range (TIR) by 10-15% and reduce hypoglycemic events.

Next-generation insulin research: Indiana University developed a smart fusion protein in 2025 that regulates glucose in mouse models via liver endogenous switches responding to high/low glucose. The protein combines insulin and glucagon functionalities, reducing hypoglycemia risk. Pediatric trials show ultra-rapid inhaled insulin improves postprandial control; once-weekly icodec outperformed degludec in 52-week trials, though with slightly higher hypoglycemia risk.

Figure 7. Structure of the smart insulin fusion protein

Key Research Targets

· RAGE (Receptor for Advanced Glycation Endproducts): A pro-inflammatory pattern recognition receptor upregulated in β cells and T cells in T1D, binding AGEs (such as HbA1c) to exacerbate inflammation. Targeting RAGE reduces inflammation and offers preventive potential.

Figure 8. RAGE signaling pathway and potential therapeutic intervention points

· Teplizumab (CD3-targeted): Delays onset and preserves C-peptide, but requires monitoring for side effects.

· JAK inhibitors (e.g., baricitinib): Block inflammation, preserve β cells; trials ongoing in 2026.

· Stem cells and gene editing: Target β cell regeneration and immune evasion.

· Insulin resistance: Metformin does not significantly reduce hepatic glucose production.

Below are abinScience's latest recombinant proteins and antibodies targeting core T1D pathways. Catalog numbers link directly to product pages.

Antibody

Kit

References:

1. Ogle GD, Wang F, Haynes A, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025;225:112277. doi:10.1016/j.diabres.2025.112277
2. Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes. Nature. 2001;414(6865):792-798. doi:10.1038/414792a
3. Evans-Molina C, Dor Y, Lernmark Å, et al. The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2025;68(9):1859-1878. doi:10.1007/s00125-025-06462-y
4. Bell KJ, Lain SJ. The Changing Epidemiology of Type 1 Diabetes: A Global Perspective. Diabetes Obes Metab. 2025;27 Suppl 6(Suppl 6):3-14. doi:10.1111/dom.16501
5. Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16(7):349-362. doi:10.1038/s41574-020-0355-7
6. Ziegler AG, Cengiz E, Kay TWH. The future of type 1 diabetes therapy. Lancet. 2025;406(10511):1520-1534. doi:10.1016/S0140-6736(25)01438-2
7. Snaith JR, Olsen N, Evans J, et al. Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial. Nat Commun. 2025;16(1):9884. Published 2025 Nov 24. doi:10.1038/s41467-025-65951-1
8. Henriques FL, Buckle I, Forbes JM. Type 1 diabetes mellitus prevention: present and future. Nat Rev Endocrinol. 2025;21(10):608-622. doi:10.1038/s41574-025-01128-6
9. Addissouky, T.A., Ali, M.M.A., El Sayed, I.E.T. et al. Type 1 diabetes mellitus: retrospect and prospect. Bull Natl Res Cent 48, 42 (2024). https://doi.org/10.1186/s42269-024-01197-z